| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2330-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-314
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3233 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate |
2007-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2009-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2009532036-A |
| titleOfInvention |
Compositions and methods for suppression of Eg5 gene expression |
| abstract |
The invention relates to expression of an Eg5 gene (Eg5 gene) comprising an antisense strand that is less than 30 nucleotides in length, generally 19-25 nucleotides in length, and having a nucleotide sequence that is substantially complementary to at least a portion of the Eg5 gene. It is related with the double stranded ribonucleic acid (dsRNA) for suppressing. The invention also includes a pharmaceutical composition comprising dsRNA together with a pharmaceutically acceptable carrier; a method for treating Eg5 expression and a disease induced by expression of the Eg5 gene using the pharmaceutical composition; and The present invention relates to a method for suppressing expression. |
| priorityDate |
2006-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |